Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Firefly Neuroscience Collaborates with Bright Minds for AI-Based Study
Details : The collaboration aims to analyze the data from its first-in-human Phase 1 of BMB-101, a highly selective 5-HT2C, Gq-protein biased agonist, for neuropsychiatric disorders and epilepsy.
Product Name : BMB-101
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
October 16, 2024
Lead Product(s) : SP-624
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Arrivo BioVentures
Deal Size : Inapplicable
Deal Type : Inapplicable
Firefly Neuroscience Uses Brain Analytics Platform in Phase 1 SP-624 Study
Details : SP-624 is a first-in-class SIRT6 activator, small molecule drug candidate, which is being evaluated for the treatment of patients with major depressive disorder.
Product Name : SP-624
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 15, 2024
Lead Product(s) : SP-624
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Arrivo BioVentures
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
